THE COUNCIL FOR TOBACCO RESEARCH – U.S.A., INC.

September 2, 1975

To: The Scientific Advisory Board

Subject: Human AHH Studies: A Contract Renewal Proposal From R. E. Kouri, Michrobiological Associates

As can be seen in the accompanying progress report a great deal has been accomplished over the past year to standardize the AHH assay to the point that this test could be used to sample lung cancer and control populations. The lymphocyte is one of the few tissues readily available, but the enzyme level is very low unless the cells are in blast state. Because of the difficulties of growing lymphocytes a large day to day variance has been observed. Some progress has been made, and the assay has been improved measurably. However, the reproducibility is still a problem.

Microbiological's Dr.R. Kouri has been a pioneer in AHH genetic studies in animals, and is now a recipient of supplementary contracts from the N.C.I. to study and improve the human AHH assay, along with Dr. T. Yamouchi (also a CTR grantee with Dr. C. Shaw at M. D. Anderson), and Dr. Ken Paigen (Roswell Park). These laboratories are collaborating closely to achieve an adequate testing system. It would seem appropriate to continue this work for another year.

In similar regard it has been suggested that renewal Grant No. 1013R1 to Dr. Malcolm Pike (under Drs. M. Gardner and B. Henderson) of the U. of S. C. be held in abeyance until a successful test system has been developed. A small grant ($10-15,000) to cover U.S.C. staff time in obtaining and shipping lung cancer and control samples for testing reproducibility, field procedures, etc., would be adequate to assure continuity and access. Should the originally proposed human lung cancer - AHH genetic field study become a possibility in the future increased funding could be requested and Scientific Advisory Board approval sought.

JHK:wg

J.H.K.

1003536027